Oppenheimer Sticks to Their Buy Rating for Cognition Therapeutics (CGTX)
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
Buy Rating Affirmed for Cognition Therapeutics Amid Promising CT1812 Clinical Trials
Oppenheimer Sticks to Its Buy Rating for Cognition Therapeutics (CGTX)
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.